Allspring Global Investments Holdings LLC Cuts Position in United Therapeutics Co. (NASDAQ:UTHR)

Allspring Global Investments Holdings LLC decreased its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 53.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 84,608 shares of the biotechnology company's stock after selling 96,697 shares during the period. Allspring Global Investments Holdings LLC owned approximately 0.19% of United Therapeutics worth $30,349,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of UTHR. Newbridge Financial Services Group Inc. purchased a new stake in shares of United Therapeutics during the 4th quarter valued at about $25,000. Brooklyn Investment Group bought a new position in United Therapeutics during the third quarter valued at approximately $33,000. Capital Performance Advisors LLP purchased a new stake in United Therapeutics in the third quarter worth approximately $82,000. MassMutual Private Wealth & Trust FSB grew its position in United Therapeutics by 31.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock worth $85,000 after purchasing an additional 58 shares during the period. Finally, Values First Advisors Inc. purchased a new stake in United Therapeutics during the 3rd quarter valued at $90,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. The Goldman Sachs Group raised their price target on United Therapeutics from $243.00 to $302.00 and gave the stock a "neutral" rating in a research note on Friday, November 1st. StockNews.com upgraded United Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Thursday, January 16th. LADENBURG THALM/SH SH increased their price objective on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a "buy" rating in a research note on Thursday, October 31st. Oppenheimer raised their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an "outperform" rating in a report on Thursday, October 31st. Finally, HC Wainwright upped their target price on shares of United Therapeutics from $400.00 to $425.00 and gave the company a "buy" rating in a report on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $382.08.

Insider Activity

In related news, COO Michael Benkowitz sold 10,000 shares of the business's stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $372.75, for a total value of $3,727,500.00. Following the transaction, the chief operating officer now directly owns 2,577 shares of the company's stock, valued at approximately $960,576.75. The trade was a 79.51 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Paul A. Mahon sold 7,700 shares of the stock in a transaction that occurred on Thursday, November 21st. The shares were sold at an average price of $367.36, for a total transaction of $2,828,672.00. Following the sale, the executive vice president now directly owns 36,710 shares of the company's stock, valued at approximately $13,485,785.60. This trade represents a 17.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 121,864 shares of company stock worth $44,516,965 over the last ninety days. Corporate insiders own 11.90% of the company's stock.

United Therapeutics Trading Up 2.1 %

Shares of UTHR traded up $7.76 during trading hours on Wednesday, reaching $380.59. 357,701 shares of the stock traded hands, compared to its average volume of 328,150. The company has a market cap of $16.99 billion, a P/E ratio of 16.71, a price-to-earnings-growth ratio of 0.96 and a beta of 0.57. The company's 50-day moving average price is $362.21 and its two-hundred day moving average price is $359.74. United Therapeutics Co. has a 52-week low of $213.75 and a 52-week high of $417.82.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.